No Data
Analysis of the Cabio Biotech(Wuhan) acquisition case: How does the symbol Ouyi Bio support a valuation of 1.3 billion with earnings of 0.043 billion over three quarters?|Focus
① Jinzheng Assessment stated that future expected profitability is at the core of a company's value, and it is estimated that Ouyi Biological's revenue will reach 0.48 billion yuan, 0.558 billion yuan, and 0.637 billion yuan from 2025 to 2027 respectively; ② "Valuation inclusivity does not mean accepting overvaluations, but rather accepting valuations that clearly analyze the business logic and valuation logic of mergers and acquisitions," said Lin Li, president of Jinzheng Assessment.
The trade price is 0.831 billion yuan! Cabio Biotech(Wuhan) disclosed the latest restructuring plan: it intends to reduce one trading counterpart and raise 0.269 billion yuan through a private placement.
① Both parties signed a performance commitment, promising that the Net income of Ouyi Biotech will not be less than 0.27 billion yuan in total for the fiscal years 2025, 2026, and 2027; ② The profits of Cabio Biotech(Wuhan) are expected to further increase. The company estimates that its revenue for the first three quarters of 2024 will rise from 0.387 billion yuan before the Trade to 0.655 billion yuan; the Net income attributable to the parent company will increase from 83.8902 million yuan to 0.113 billion yuan.
Jiabiyou: Jiabiyou Biotechnology (Wuhan) Co., Ltd. 2024 Annual Performance Report Announcement
Jiabiyou Biotechnology (Wuhan) Co., Ltd. 2024 Annual Results Express Announcement
Cabio Biotech(Wuhan) (688089.SH): The net income for the fiscal year 2024 is 0.124 billion yuan, an increase of 35.25% year-on-year.
On February 27, Gelonghui reported that Cabio Biotech (Wuhan) (688089.SH) announced its performance summary for the fiscal year 2024, achieving revenue of 0.555 billion yuan, an increase of 25.06% compared to the same period last year; net income attributable to the parent company's owners was 0.124 billion yuan, an increase of 35.25% compared to the same period last year; net income attributable to the parent company owners, excluding non-recurring gains and losses, was 0.1 billion yuan, an increase of 60.57% compared to the same period last year. The growth in the company's performance during the reporting period was driven by the dual engines of domestic and international markets along with the release of new production capacity from fundraising investments. The growth in domestic business benefited from the continued release of the new national standard bonus.
Cabio Biotech(Wuhan) (688089.SH) has newly recognized Liu Yang, Yu Chao, and Tang Xiaopeng as core technical personnel.
Cabio Biotech(Wuhan) (688089.SH) announced that the company's core technical staff member, Xiao Min, has resigned for personal reasons, and after leaving...